Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

PURPOSE: Non-alcoholic fatty liver disease (NAFLD) affects about 75% of patients with type 2 diabetes mellitus (T2DM). We conducted a meta-analysis to determine the effect of canagliflozin on fatty liver indexes in T2DM patients. METHODS: A literature search of PubMed, Embase and Cochrane was conduc...

Full description

Bibliographic Details
Main Authors:	Boyu Li, Ying Wang, Zhikang Ye, Hui Yang, Xiangli Cui, Zhenjun Wang, Lihong Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-06-01
Series:	Journal of Pharmacy & Pharmaceutical Sciences
Online Access:	https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/29831

Similar Items

Antidepressant Use and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis
by: Ying Wang, et al.
Published: (2019-01-01)

Effectiveness of Pharmacist-led Anticoagulation Management on Clinical Outcomes: A Systematic Review and Meta-Analysis
by: Kelu Hou, et al.
Published: (2018-01-01)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
by: Syed Raza Shah, et al.
Published: (2018-09-01)

Clinical Outcomes with Antiviral Prophylaxis or Preemptive Therapy for Cytomegalovirus Disease after Liver Transplantation: A Systematic Review and Meta-Analysis
by: yang hui, et al.
Published: (2017-01-01)

Canagliflozin - Beginning of the journey
by: Sunil Kumar Pandey, et al.
Published: (2014-01-01)

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
by: Yanjun Cui, et al.
Published: (2022-08-01)

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats
by: Takahiro Oguma, et al.
Published: (2015-04-01)

Canagliflozin-Induced Diabetic Ketoacidosis
by: Jessica Turner MSIV, et al.
Published: (2016-08-01)

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) - A randomized placebo-controlled trial
by: Neal, B, et al.
Published: (2013)

Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials
by: Qianqian Ma, et al.
Published: (2022-09-01)

Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial
by: Daniel Guldager Kring Rasmussen, et al.
Published: (2022-11-01)

Patient profiling in diabetes and role of canagliflozin
by: Amblee A
Published: (2014-11-01)

Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis
by: Marco Castellana, et al.
Published: (2021-04-01)

Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
by: Xi-Xi He, et al.
Published: (2016-01-01)

Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials
by: Shu-ting Wang, et al.
Published: (2020-03-01)

EMPA-REG OUTCOME trial and Canagliflozin Cardiovascular Assessment Study: Looking beyond the obvious
by: Rishad Ahmed, et al.
Published: (2017-01-01)

Effects of garlic supplementation on non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials
by: Leilei Yu, et al.
Published: (2022-12-01)

Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial
by: Atsushi Tanaka, et al.
Published: (2022-12-01)

Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial
by: Ying-ying Yu, et al.
Published: (2022-11-01)

Evaluation Outcomes Associated with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis
by: Hui Yang, et al.
Published: (2016-08-01)

Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Ruxin Wang, et al.
Published: (2022-07-01)

Canagliflozin combined with aerobic exercise protects against chronic heart failure in rats
by: Helin Sun, et al.
Published: (2024-03-01)

The Diagnostic and Prognostic Value of the Triglyceride-Glucose Index in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): A Systematic Review and Meta-Analysis
by: Jing Wang, et al.
Published: (2022-11-01)

In vivo assessment of the pharmacokinetic interactions between donafenib and dapagliflozin, donafenib and canagliflozin in rats
by: Xueru He, et al.
Published: (2023-06-01)

Probiotics for the improvement of metabolic profiles in patients with metabolic-associated fatty liver disease: A systematic review and meta-analysis of randomized controlled trials
by: Qiuhong Wang, et al.
Published: (2022-11-01)

Combining serum uric acid and fatty liver index to improve prediction quality of nonalcoholic fatty liver disease
by: Yajie Ding, et al.
Published: (2023-01-01)

Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial
by: Abhinav Sharma, et al.
Published: (2024-02-01)

Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials
by: Zeyu Wang, et al.
Published: (2023-03-01)

The Effects of Olive Oil Consumption on Biochemical Parameters and Body Mass Index of People with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Georgios Tsamos, et al.
Published: (2024-03-01)

The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis—Systematic Review and Meta-Analysis
by: Abdulrahman Ismaiel, et al.
Published: (2021-12-01)

Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial
by: Akira Sezai, et al.
Published: (2022-07-01)

Canagliflozin and risk of amputation in patients with type 2 diabetes
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Emerging treatments in type 2 diabetes: focus on canagliflozin
by: Rosiak M, et al.
Published: (2014-08-01)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
by: Curtis Triplitt, et al.
Published: (2015-01-01)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
by: Curtis Triplitt, et al.
Published: (2015-10-01)

Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: P. Ebrahimpour, et al.
Published: (2024-03-01)

Comparison of Machine Learning Models and the Fatty Liver Index in Predicting Lean Fatty Liver
by: Pei-Yuan Su, et al.
Published: (2023-04-01)

Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population
by: Eun-Ju Cho, et al.
Published: (2021-11-01)

Double‐blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery: A pilot study
by: Sangeeta R. Kashyap, et al.
Published: (2020-06-01)

Effectiveness of Valganciclovir 900mg Versus 450mg for Cytomegalovirus Prophylaxis in Renal Transplantation: A Systematic Review and Meta-Analysis
by: wang xin, et al.
Published: (2017-07-01)